Study of Systematic Data Feedback to Improve Treatment and Survival in Patients with ST-Elevation Myocardial Infarction STEMI
Led by Karl Heinrich Scholz · Updated on 2023-03-30
50000
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether formalized data assessment and systematic feedback can improve treatment times and survival rates for patients with ST-segment elevation myocardial infarction STEMI. The study focuses on reducing time intervals from patient contact to balloon inflation during percutaneous coronary intervention PCI and aims to enhance outcomes through continuous performance feedback in a multicenter setting. This project is structured in multiple phases to test, implement, and advance these feedback methods across various hospitals with PCI capability.
The study includes a behavioral intervention where data on treatment times and clinical outcomes are collected and analyzed quarterly. These results are shared with cardiology, emergency department, and emergency medical services staff in interactive sessions to identify and address areas for improvement. The trial spans several phases an initial pilot phase, an implementation phase involving multiple centers, and an advanced phase developing an automated, standardized feedback tool. Feedback sessions occur quarterly or annually depending on the phase.
Participants are all patients diagnosed with STEMI and transferred to PCI centers for treatment. The study collects web-based data on time from first medical contact to balloon inflation over consecutive three-month periods. Researchers measure treatment times as the primary outcome and mortality rates at hospital discharge, 30 days, and one year as secondary outcomes. The study involves repeated data feedback sessions to hospital and emergency staff and aims to monitor and improve care quality over time through systematic evaluation.
CONDITIONS
Brief Title
Feedback Intervention and Treatment Times in ST- Elevation Myocardial Infarction
Research Team
K
Karl H. Scholz, MD.
T
Thomas Meyer, MD. PHD.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
All patients diagnosed with STEMI and transported to the primary PCI center intending to undergo primary PCI
STEMI defined by elevation of ST-segments ≥ 0.1 mV in at least two contiguous leads or new/presumed new left bundle branch block with typical symptoms
You will not qualify if you...
STEMI patients with infarct-related symptoms lasting longer than 24 hours
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Outpatient Treatment
Duration - Up to 18 months (six consecutive 3-month periods)
Participants receive systematic data feedback intervention aimed at improving treatment times for STEMI through quarterly meetings with staff to review performance and discuss potential improvements.
Quarterly feedback meetings for up to 18 months
Long-term Monitoring
Duration - Up to 1 year after treatment
Participants are monitored for mortality outcomes including in-hospital, 30-day, and 1-year mortality following treatment.
Follow-up assessments at hospital discharge, 30 days, and 1 year
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
1
Similar Trials
Study of Adults With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Tracking Heart and Health Outcomes Over Time
Study of Ziltivekimab Compared to Placebo to Reduce Heart Vessel Plaque After a Heart Attack
Evaluating AI Software Accuracy for Heart Pumping Function Using the Peerbridge COR ECG Wearable Monitor
Comparison of Rivaroxaban and Warfarin for Treating Left Ventricular Blood Clots After Heart Attack in Nepal
A Randomized Study at a Tertiary Cardiac Center
Studying Anxiety, Stress, and PTSD After a Heart Attack in Adults Aged 19 to 90
Study of Ticagrelor Alone Compared to Ticagrelor Plus Aspirin in Adults With Medically Treated Myocardial Infarction
Genetic-Guided Early Switch to Low-Potency Single Antiplatelet Therapy Versus High-Potency Therapy to Reduce Bleeding in High-Risk Patients After Acute Coronary Syndrome
Barts Revascularisation Registry to Understand Patient Characteristics and Outcomes in Coronary Artery Disease at Barts Heart Centre
Barts Sex-CAD Database Studying Sex Hormones and Inflammation in Coronary Artery Disease to Understand Differences in Women and Men
Real-World Study of Patients Aged 16 and Older with Myocardial Infarction and Non-Obstructive Coronary Arteries MINOCA
Tracking Diagnosis and Outcomes at Barts Health NHS Trust
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial.
Karl Heinrich Scholz, Sebastian K G Maier, Lars S Maier...
Contact-to-balloon time and door-to-balloon time after initiation of a formalized data feedback in patients with acute ST-elevation myocardial infarction.
Karl Heinrich Scholz, Reinhard Hilgers, Dorothe Ahlersmann...
Infarct-Related Artery as a Donor of Collaterals in ST-Segment-Elevation Myocardial Infarction With Concomitant Chronic Total Occlusion: Challenge of the Double-Jeopardy Thesis.
Letter by Maier et al regarding article, "Emergency department bypass for ST-segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline Program".
Lars S Maier, Sebastian K G Maier, Karl Heinrich Scholz
[Optimizing systems of care for patients with acute myocardial infarction. STEMI networks, telemetry ECG, and standardized quality improvement with systematic data feedback].
Karl Heinrich Scholz, Georg von Knobelsdorff, Dorothe Ahlersmann...
Pre-hospital heparin is not associated with infarct vessel patency and mortality in ST-segment elevation myocardial infarction patients with out-of-hospital cardiac arrest.
Phillip Scholz, Tim Friede, Karl Heinrich Scholz...